On the evening of July 22, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (600332. SH) announced that the company's board of directors received a written resignation report submitted by the company's chairman Mr. Li Chuyuan on July 22, 2024. Mr. Li Chuyuan resigned as the chairman of the ninth board of directors, an executive director and the chairman of the strategic development and investment committee of the board of directors of the company due to personal reasons. After his resignation, Li Chuyuan no longer held any position in the company. According to the announcement, Mr. Li Chuyuan confirmed that there is no difference of opinion with the company's board of directors, and there are no other matters that need to be brought to the attention of the company's shareholders.
"FMCG" learned that Li Chuyuan has been the vice chairman of Baiyunshan since June 28, 2010, and the chairman of Baiyunshan since August 8, 2013, and so far, Li Chuyuan has been at the helm of Baiyunshan for nearly 11 years. On July 22, the twelfth meeting of the ninth board of directors of Baiyunshan deliberated and agreed that Yang Jun, its vice chairman, would perform the duties of the chairman on his behalf, and the period would be from the date of approval of the board of directors to the date of election of the new chairman of the board of directors.
Chairman of Baiyun Mountain
Mr. Li Chuyuan
In the first quarter of 2023 and 2024, Baiyunshan will achieve net profit attributable to the parent company of 4.056 billion yuan and 1.958 billion yuan respectively, a year-on-year increase of 2.25% and 2.59% respectively. During the reporting period, affected by factors such as drug price reductions and raw material price increases, the main economic indicators of the pharmaceutical industry were in a downward trend, and the operation trend of various sub-industries continued to diverge. The pharmaceutical industry in which Baiyunshan is located is still in an important window period of transformation and upgrading.